United States: FDA Finalizes Key Guidance Documents On Biosimilars

Last Updated: May 1 2015
Article by Joanne S. Hawana

On the heels of its approval of the first biosimilar product in March, FDA has just released final versions of three key biosimilar guidance documents under the Biologics Price Competition and Innovation Act (BPCIA). The newly finalized documents update draft guidance documents published in February 2012. Together, the three final guidance documents present FDA's approach for determining biosimilarity and the critical scientific and quality issues that sponsors will need to address in their so-called "351(k) applications" (named after the new section added to the Public Health Service Act by the BPCIA).

Scientific Considerations in Demonstrating Biosimilarity

The first finalized guidance document, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, lays out the approach that sponsors should take when developing the evidence needed to demonstrate biosimilarity to a reference product, as well as FDA's "totality-of-the-evidence" approach for reviewing biosimilar applications. In addition, it discusses general scientific principles for sponsors to consider when performing:

  • structural and functional analyses of the proposed biosimilar;
  • animal toxicity studies;
  • human pharmacokinetic and pharmacodynamic studies;
  • clinical immunogenicity assessments; and
  • clinical safety and effectiveness studies.

The substantive information in this final guidance mirrors what the Agency presented in the 2012 draft guidance document, although some changes were made to clarify and reorganize the recommendations. Notably, the Agency continues to encourage sponsors to consult with FDA early and often during the biosimilar development process because "the type and amount of analyses and testing that will be sufficient to demonstrate biosimilarity will be determined on a product-specific basis."

Quality Considerations in Demonstrating Biosimilarity

The second guidance document addresses Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product and deals with the technical aspects of "chemistry, manufacturing, and controls" (CMC) information for a proposed biosimilar application. Significant changes in the finalized version of this guidance include a more detailed discussion about the need for "bridging data" when a non-U.S.-licensed comparator biologic is used in certain studies supporting a demonstration of biosimilarity to a U.S.-licensed reference product, as well as expanded descriptions on characterizing impurities in the biosimilar product that may be different than impurities in the reference product. The take-home message of this guidance continues to be that "proteins are very sensitive to their environment" – thus, for example, even the primary packaging for the product should to be analyzed in comparison to the reference product's packaging to determine whether product stability or clinical performance is adversely affected.

Questions and Answers

Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 is the third guidance document, organized (as evident from the title) into a question and answer (Q&A) format. FDA has positioned this as a living document that will be updated with new Q&As as necessary. The recently released iteration finalizes many of the Q&As that were presented for comment in the February 2012 draft version, but it omits several questions (presumably due to an inability to finalize the Agency's answers at this point in time) and also indicates that a few of the draft Q&As are in the process of being revised and will be released again for public comment. Of particular note, a draft Q&A regarding whether a sponsor can request a determination from FDA on interchangeability as part of the original 351(k) application has been omitted.

Significant Questions Remain

Despite the publication of this final guidance for industry, many of the more contentious questions surrounding the new regulatory pathway for biosimilars remain unanswered by FDA. Draft guidance on biosimilar "naming" reportedly was sent last year to the Department of Health and Human Services for review and approval before FDA releases the draft for public comment. The two sides of the naming issue continue to disagree about whether a biosimilar's nonproprietary name should be the same as that of the reference product, and whether and to what degree this will affect product tracking and post-market safety surveillance. A final decision on naming conventions may also have practical implications for pharmacy, PBM, and payor operations, including formulary development.

In addition, the Agency has yet to provide any guidance on what will be necessary to establish the interchangeability of an approved biosimilar. As noted in our recent blog post regarding state activity on biosimilar substitution laws, the sponsor of the recently approved biosimilar product, Zarxio, did not seek an interchangeability decision from FDA. Whether or not a biosimilar is "interchangeable" will be critical in determining whether pharmacists may substitute the biosimilar for its prescribed reference product, given that most states acting to impose limits on such substitution are requiring the biosimilar first to be approved by FDA as interchangeable.

Other scientific and technical questions for which industry is seeking more specific guidance from FDA include what standards must be met for indication extrapolation and labeling requirements. The Zarxio approval provides some insight into FDA's thinking on these issues. The Agency approved Zarxio for use in all five of the labeled indications of its reference product (Neupogen), even though the sponsor did not study the biosimilar for each indication, and the labeling for Zarxio is almost identical to that of its reference product. Accordingly, FDA did permit indication extrapolation for this well-characterized protein product. Indication extrapolation may be more difficult to obtain from the Agency for a product with a less well-characterized mechanism of action. This would track the trend observed so far with biosimilars approved for marketing in Europe.

We will continue to keep our readers apprised of any developments from FDA, CMS, or the states on these important issues and others related to biosimilars.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions